StockNews.AI
ILMN
StockNews.AI
182 days

Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference

1. Illumina to host an investor session at AGBT conference on Feb 25, 2025. 2. CEO, CFO, and CTO will present insights during the live webcast. 3. Webcast available on Illumina's website for 30 days post-event. 4. Illumina focuses on genome innovation, impacting healthcare and research markets.

3m saved
Insight
Article

FAQ

Why Neutral?

Investor sessions typically do not cause immediate stock movement. However, updates may indirectly influence investor sentiment and clarity.

How important is it?

The investor session may enhance transparency but may not provide revolutionary changes to direction or performance.

Why Short Term?

Short-term effects possible if new growth strategies or financial plans are revealed. Historical events suggest market reactions can vary based on information presented.

Related Companies

Illumina Announces Live Webcast of Upcoming Investor Session

SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session at the AGBT conference.

The investor fireside chat will begin at 8:00am Pacific Time (11:00am Eastern Time) on Tuesday, February 25, 2025 and will feature Jacob Thaysen (Chief Executive Officer), Ankur Dhingra (Chief Financial Officer), and Steve Barnard (Chief Technology Officer).

Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link – https://illumina-agbt-investor-session-feb-2025.open-exchange.net/. To ensure timely connection, please join at least ten minutes before the scheduled start of the session.

A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contact Information

Investors: Salli Schwartz +1.858.291.6421 [email protected]

Media: Bonny Fowler +1.740.641.5579 [email protected]

SOURCE Illumina, Inc.

Related News